Evidence map›Paper›PMID 27531847›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016

Plasmodium Parasitemia Associated With Increased Survival in Ebola Virus-Infected Patients.

Kyle Rosenke, Jennifer Adjemian, Vincent J Munster, Andrea Marzi, Darryl Falzarano, Clayton O Onyango, Melvin Ochieng, Bonventure Juma, Robert J Fischer, Joseph B Prescott and 31 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. A systematic review and meta-analysis of patient data from the West Africa (2013-16) Ebola virus disease epidemic.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2019
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. What treating Ebola means for pandemic influenza.Journal of public health policy · 2018
    Article
  17. When do co-infections matter?Current opinion in infectious diseases · 2018
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors at 10 institutions in 5 countries.

Kyle RosenkeLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Jennifer AdjemianEpidemiology Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda Commissioned Corps, US Public Health Service, Rockville, Maryland.
Vincent J MunsterLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Andrea MarziLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Darryl FalzaranoLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Clayton O OnyangoCenter for Global Health, Division of Global Health Protection, Centers for Disease Control and Prevention.
Melvin OchiengKenya Medical Research Institute, Center for Global Health Research, Nairobi.
Bonventure JumaCenter for Global Health, Division of Global Health Protection, Centers for Disease Control and Prevention.
Robert J FischerLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Joseph B PrescottLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
David SafronetzLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Victor OmballaKenya Medical Research Institute, Center for Global Health Research, Nairobi.
Collins OwuorKenya Medical Research Institute, Center for Global Health Research, Nairobi.
Thomas HoenenLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Allison GrosethLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Cynthia MartellaroLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Neeltje van DoremalenLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Galina ZemtsovaCenters for Disease Control and Prevention, Atlanta, Georgia.
Joshua SelfCenters for Disease Control and Prevention, Atlanta, Georgia.
Trenton BushmakerLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Kristin McNallyLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Thomas RoweCenters for Disease Control and Prevention, Atlanta, Georgia.
Shannon L EmeryCenters for Disease Control and Prevention, Atlanta, Georgia.
Friederike FeldmannRocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratories, National Institutes of Health, Hamilton, Montana.
Brandi N WilliamsonLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Sonja M BestLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Tolbert G NyenswahMinistry of Health and Social Welfare/Incident Management System, Monrovia, Liberia.
Allen GrollaSpecial Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba.
James E StrongSpecial Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba.
Gary KobingerSpecial Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba.
Fatorma K BolayLiberian Institute for Biomedical Research, Charlesville.
Kathryn C ZoonCytokine Biology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Jorgen StassijnsMédecins Sans Frontières, Operational Center, Brussels, Belgium.
Ruggero GiulianiMédecins Sans Frontières, Operational Center, Brussels, Belgium.
Martin de SmetMédecins Sans Frontières, Operational Center, Brussels, Belgium.
Stuart T NicholCenters for Disease Control and Prevention, Atlanta, Georgia.
Barry FieldsCenter for Global Health, Division of Global Health Protection, Centers for Disease Control and Prevention.
Armand SprecherMédecins Sans Frontières, Operational Center, Brussels, Belgium.
Moses MassaquoiMinistry of Health and Social Welfare/Incident Management System, Monrovia, Liberia.
Heinz FeldmannLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Emmie de WitLaboratory of Virology, Division of Intramural Research, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
National Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USCenters for Disease Control and Prevention · USMédecins Sans Frontières · BECenter for Global Health · USKenya Medical Research Institute · KEPublic Health Agency of Canada · CAMinistry of Health and Social Welfare · LRLiberian Institute for Biomedical Research · LRUnited States Public Health Service Commissioned Officers Association · US

Funding

Viral Hemorrhagic Fevers: Disease Modeling and TransmissionZIAAI001089 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FELDMANN, HEINRICH · 2009 to 2025
$50.7M
Virus-Host Interactions: Induction and Evasion of Host Innate ImmunityZIAAI001125 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BEST, SONJA · 2010 to 2025
$28.1M
Virus Ecology UnitZIAAI001179 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MUNSTER, VINCENT · 2013 to 2025
$24.3M
International Research in CongoZIAAI001190 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MUNSTER, VINCENT · 2014 to 2025
$3.4M
6 · The paper itself

Abstract

backgroundThe ongoing Ebola outbreak in West Africa has resulted in 28 646 suspected, probable, and confirmed Ebola virus infections. Nevertheless, malaria remains a large public health burden in the region affected by the outbreak. A joint Centers for Disease Control and Prevention/National Institutes of Health diagnostic laboratory was established in Monrovia, Liberia, in August 2014, to provide laboratory diagnostics for Ebola virus.

methodsAll blood samples from suspected Ebola virus-infected patients admitted to the Médecins Sans Frontières ELWA3 Ebola treatment unit in Monrovia were tested by quantitative real-time polymerase chain reaction for the presence of Ebola virus and Plasmodium species RNA. Clinical outcome in laboratory-confirmed Ebola virus-infected patients was analyzed as a function of age, sex, Ebola viremia, and Plasmodium species parasitemia.

resultsThe case fatality rate of 1182 patients with laboratory-confirmed Ebola virus infections was 52%. The probability of surviving decreased with increasing age and decreased with increasing Ebola viral load. Ebola virus-infected patients were 20% more likely to survive when Plasmodium species parasitemia was detected, even after controlling for Ebola viral load and age; those with the highest levels of parasitemia had a survival rate of 83%. This effect was independent of treatment with antimalarials, as this was provided to all patients. Moreover, treatment with antimalarials did not affect survival in the Ebola virus mouse model.

conclusionsPlasmodium species parasitemia is associated with an increase in the probability of surviving Ebola virus infection. More research is needed to understand the molecular mechanism underlying this remarkable phenomenon and translate it into treatment options for Ebola virus infection.

Indexed as

CoinfectionEbolavirusParasitemiaAdolescentAdultAgedAged, 80 and overAnimalsChildChild, PreschoolDisease Models, AnimalFemaleHemorrhagic Fever, EbolaHumansInfantInfant, Newborncoinfectionebolavirusplasmodiumsurvival

Identifiers

PMID27531847
PMCPMC5036915
OpenAlexW2516047054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.